Compare Cudis (CUDIS) vs Enzyme (MLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cudis vs Enzyme — how do they compare? Cudis trades at Rp87.33 (market cap Rp21,88M, Rp81,53M 24h volume), while Enzyme trades at Rp30,212 (market cap Rp134,13M, Rp104,56M 24h volume). The key difference: Enzyme is far larger — about 6.1× Cudis's market cap, and Cudis's supply is capped (247,5M / 1B CUDIS (25%)) while Enzyme's keeps growing. Which is the better fit depends on your goals — on Pluang, investors hold Cudis for 11 Days and Enzyme for 28 Days on average.
| CUDIS | MLN | |
|---|---|---|
Market Cap | Rp21,88M | Rp134,13M |
Volume (24h) | Rp81,53M | Rp104,56M |
Circulating Supply | 247,5M / 1B CUDIS (25%) | 3,3M MLN |
Typical Hold Time | 11 Days | 28 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cudis is trading at Rp87.293 with a market cap of Rp21.8M, showing a bearish technical outlook as moving averages signal strong selling pressure and oscillators remain neutral. The asset is near resistance at Rp86 with support at Rp80, while RSI_6 at 13.35 indicates potential oversold conditions. No recent protocol updates or ecosystem developments have been noted, and the token's circulating supply is 247.5M out of a 1B max supply, with a 25% circulation rate.
Overall, the outlook is cautious due to bearish signals and low liquidity, but the oversold RSI may present a short-term opportunity. Major risks include high volatility, limited exchange depth, and regulatory uncertainty in crypto markets. Investors should monitor for any network activity shifts or exchange listings that could impact price dynamics.
Enzyme (MLN) shows a market cap of Rp134,13M with a circulating supply of 3,3jt tokens. The asset's price data is currently unavailable, but the hold time of 28 days suggests moderate trader retention. Recent news on ETF inflows may indirectly affect crypto sentiment, though no direct protocol updates are noted. Trading volumes and network activity metrics require verification from live crypto data sources for a complete picture.
Outlook: Enzyme faces typical crypto volatility risks with limited recent fundamental developments. Opportunities may arise from broader market trends, but investors should monitor liquidity and regulatory shifts closely. Major risks include low market cap susceptibility to manipulation and absence of max supply clarity.
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cudis
CUDIS is creating the first-ever Longevity Protocol aimed at making longevity trackable, personalized, and rewarding. By integrating the CUDIS Ring, an AI-powered Longevity Hub, and a blockchain-driven Super App, users will have complete ownership of their health data, receive real-time insights on their longevity, and gain economic incentives for optimizing their biological health. CUDIS is building a new ecosystem for longevity that includes realistic and effective products, programs, and services, in collaboration with partners around the world.
Read more on CUDIS →About Enzyme
Enzyme is an easy-to-use on-chain asset management system that enables access to digital assets and DeFi from one simple, unified app. It provides a front-to-back execution and order management system, which provides fully automated reporting, risk management, administration, governance and operations.
Read more on MLN →
